Mesa Laboratories vs Maravai Lifesciences Holdings
Mesa Laboratories is the larger business, with $249m of revenue in fiscal 2026 against $186m for Maravai Lifesciences Holdings (1.3 times as much). Mesa Laboratories grew faster (3.4% against -28.3%). Mesa Laboratories kept more of each dollar of sales as profit: a net margin of 2.7% against -70.4%. Mesa Laboratories carries less debt relative to equity (36.2% against 138.5%).
| Latest fiscal year | Mesa LaboratoriesMLAB, 2026 | Maravai Lifesciences HoldingsMRVI, 2025 |
|---|---|---|
| Revenue | $249m | $186m |
| Revenue growth | 3.4% | -28.3% |
| Net income | $6.7m | −$131m |
| Operating margin | 7.4% | -115.9% |
| Net margin | 2.7% | -70.4% |
| Return on equity | 3.9% | -48.6% |
| Free cash flow | $39.6m | −$70.7m |
| Cash | $26.9m | $217m |
| Total debt | $67.5m | $294m |
| Debt to equity | 36.2% | 138.5% |
| Dividend per share | $0.64 | — |
| Dividend yield | 0.5% | — |
| Share buybacks | — | — |
| Employees | 717 | 435 |
| Market value | $683m | $1.06bn |
| Price vs our value range | Within our value range | — |
| Moat score | 44 (Weak) | 23 (Weak) |
| Insider trades, 12 months | 5 buys, 7 sales | 5 buys, 2 sales |